Please assess the completion status of the following clinical trial:

Trial Title: A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with CHF who exhibit edema, jugular venous distention, hepatomegaly, pulmonary congestion, or 3rd sound due to extracellular volume expansion~2. Hospitalized patients or patients who can be hospitalized for the study from the commencement of the observation period to the end-of-study examination~3. Men and women between the ages of 20 and 80 (non-inclusive) at the time of giving consent~4. Patients who have taken furosemide at 40 mg/d or more (oral dosing) without alteration of dosage for the 3 days of the observation period~5. Patients whose body weight has been stable (±1.0 kg) for 2 days prior to commencement of study drug administration~Exclusion Criteria:~1. Patients with unstable heart failure (acute heart failure, acute exacerbation of chronic heart failure, etc)~2. Patients with an implanted ventricular assist device~3. Patients who have undergone or are scheduled to undergo any of the following procedures~   * Heart surgery involving thoracotomy within 60 days prior to the screening examination~  * Pacemaker implant surgery involving bilateral pacing within 60 days prior to the screening examination~  * Angioplasty, electrophysiologic device implantation, ventricular assist device implantation, heart transplant, or other cardiac surgery scheduled within 30 days after the screening examination~4. Patients with any of the following diseases, complications, or symptoms~   * Suspected hypovolemia~  * Onset of acute myocardial infarction within 30 days prior to the screening examination~  * Hypertrophic cardiomyopathy (excluding diastolic phase)~  * Definitively diagnosed active myocarditis or amyloid cardiomyopathy~  * Valvular heart disease with significant stenosis~  * Untreated thyroid disease~  * Progressive neurological disease (Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc) or severe episodic neurological disease (epilepsy, Guillain-Barre syndrome, etc)~  * Diabetes with poor glycemic control~  * Anuria~  * Hepatic coma~  * Hyponatremia of moderate or greater severity (serum Na \< 120 mEq/L)~5. Patients with a history of the following conditions~   * Occurrence of sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to the screening examination (except for patients using an implantable cardioverter-defibrillator)~  * Evident cerebral infarction~  * Multiple stroke~  * Occurrence of a cerebrovascular accident within 30 days prior to the screening examination~  * Hypersensitivity or idiosyncratic reaction to benzazepine derivatives, such as benazapril~6. Patients with a history of drug abuse or alcoholism in the past year~7. Patients in a state of morbid obesity with a body mass index (weight\[kg\] ÷ height \[m\]2) over 35~8. Patients with a supine systolic arterial blood pressure of less than 90 mmHg~9. Patients with any of the following abnormal laboratory values: Hemoglobin \<9 g/dL, total bilirubin \>3.0 mg/dL, serum creatine \>3.0 mg/dL, serum Na \>147 mEq/L, or serum K \>5.5 mEq/L~10. Patients not capable of taking oral medication~11. Patients who are nursing, pregnant, capable of pregnancy, or intending to become pregnant during or shortly after the study period~12. Patients who have taken a study drug other than OPC-41061 within 30 days prior to screening~13. Patients who have previously taken OPC-41061 in this study or another study of OPC-41061~14. Patients otherwise judged by the principal investigator or attending investigator to be inappropriate for inclusion in the study (eg, patients with hepatic cirrhosis, renal disease, etc.)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).